SML0325
瑞替加滨
≥98% (HPLC)
别名:
D-23129, N-（2-氨基-4-（4-氟苄基氨基）苯基）氨基甲酸乙酯, 依佐加滨
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C16H18FN3O2
化学文摘社编号:
分子量:
303.33
UNSPSC Code:
12352200
NACRES:
NA.77
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
8072099
InChI
1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)
SMILES string
FC1=CC=C(CNC2=CC(N)=C(NC(OCC)=O)C=C2)C=C1
InChI key
PCOBBVZJEWWZFR-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
drug control
USDEA Schedule V
color
white to light brown
solubility
DMSO: >15 mg/mL
storage temp.
room temp
Quality Level
Gene Information
human ... KCNQ1(3784), KCNQ2(3785), KCNQ3(3786), KCNQ4(9132), KCNQ5(56479)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
瑞替加滨是一种 Kv7.2-7.5 钾通道激活剂； 抗惊厥药。
瑞替加滨（依佐加滨）是一种具有抗惊厥活性的 Kv7.2-7.5 （KCNQ2-5）神经元钾通道开放剂。
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 1
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Michele Y Splinter
Clinical therapeutics, 34(9), 1845-1856 (2012-08-25)
Ezogabine, also known as retigabine, is a recently approved anticonvulsant medication with a novel mechanism of action. It activates low-threshold voltage-gated potassium channels, leading to hyperpolarization of the membrane potential, stabilization of the resting membrane potential, and suppression of repetitive
Ewa Zwierzyńska et al.
Postepy higieny i medycyny doswiadczalnej (Online), 67, 973-981 (2013-10-04)
Retigabine belongs to a new generation of antiepileptic drugs. Its mechanism of action is different from that previously known. Retigabine opens potassium channels of subfamily Kv 7, especially Kv 7.2 and Kv 7.3. The drug enhances GABA-ergic transmission. It is
Emma D Deeks
CNS drugs, 25(10), 887-900 (2011-09-23)
Retigabine (ezogabine in the US) opens neuronal voltage-gated potassium channels, resulting in resting membrane potential stabilization, neuronal subthreshold excitability control and anticonvulsant effects. The clinical efficacy of adjunctive oral retigabine in adults with inadequately controlled, partial-onset seizures was demonstrated in
Carl E Stafstrom et al.
Nature reviews. Drug discovery, 10(10), 729-730 (2011-10-01)
Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the U.S. Food and Drug Administration (F.D.A.) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this
Sylvain Rheims et al.
Expert review of neurotherapeutics, 12(5), 509-517 (2012-05-04)
Ezogabine/retigabine (RTG) is a novel antiepileptic compound that activates a voltage-sensitive neuronal-specific outward potassium current that decreases neuronal excitability. RTG has been evaluated in three pivotal placebo-controlled randomized trials as adjunctive therapy in adult drug-resistant partial epilepsy. In comparison to
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持